Testing effectiveness (Phase 2)Study completedNCT02030847
What this trial is testing
Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
Who this might be right for
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
University of Pennsylvania 42